Relevium Technologies – Relevium is a publicly traded corporation strategically focused on the expansion and acquisition of entrepreneurial brands within the health and wellness sector. Our focus is on being a trusted source of high-quality nutraceutical and CBD products.
Relevium creates shareholder value by aggregating entrepreneurial health and wellness e-brands through a shared success structure that allows investors to secure excellent value at source and while seeking enhanced valuations in the public capital markets.
Biocannabix Health Corporation Inc. (“BCX”) is a wholly-owned subsidiary of Relevium Technologies with a focus on Nutraceutical and Pharmaceutical of cannabinoid infused formulations for pediatric and adult medical applications. The company’s head offices are located in Montreal, Quebec and is the process of designing and building a fully integrated organic cultivation and processing GMP facility in based in Montreal, Quebec. The brand portfolio includes Biocannabix® and Cannakids®.
BCX is building out a fully integrated organic cultivation facility based in Montreal, Quebec. The facility will house R&D and support in-house brands.
BioGanix is a cutting-edge line of weight-loss, health, beauty improvement and fitness supplements and products. BioGanix products help people lose weight, become healthier, happier, and most importantly achieve the results that our customers are looking for.
BioGanix has some of the best-selling products in the Health and Personal Care category on Amazon, and a loyal customer base. The combination of online marketing with an emphasis on superior quality products backed by stringent scientific research and formulations, this has developed BioGanix in becoming one of the leading dietary supplement brands in the U.S.
Since acquiring the BioGanix brand in 2017, Relevium grew its product line to 45 products and expanded its distribution channels as the company is now selling on Walmart.com in the United States. Relevium has also increased the BioGanix brand internationally as it is now available on Amazon.co.uk. Relevium will continue to execute on its global growth strategy with the European market insight and soon the Canadian market. Relevium will continue to innovate with the BioGanix brand, expand the product line and distribution channels to further drive growth.
BioGanix continues to increase its brand and customer base in the Health and Wellness sector through increased product offerings, distribution channels and international footprint.
What We Do
Relevium is a publicly traded corporation strategically focused the acquisition of e-retail brands, products and technologies in the health and wellness market. Relevium’s products are part of the $3.72 trillion dollar global wellness industry — one of the fastest growing worldwide markets. Our specific focus is on products that promote overall health, nutraceuticals, fitness nutrition and cosmeceuticals. The company already has 25 products being sold on Amazon with more being planned.
Who We Are
Relevium’s solid management team combines strong scientific knowledge and marketing know-how. The company leverages this experience to get the best out of the targets they acquire, while developing their own product lines.
Relevium also builds partnerships with other firms to expand their product lines. Relevium has recently announced an agreement with Salvenia Nutrition of Montreal and Biodevas Laboratories to develop an exclusive brand and product line of nutraceuticals and phytoceuticals targeted to pet care owners on a direct-to-consumer basis. Relevium has also retained Salvenia, a leading pet and livestock nutrition company, to lead the market research and the product line formulation process.
FN Media Group LLC (FNMG) owns and operates FinancialNewsMedia.com (FNM) which is a third party publisher that disseminates electronic information through multiple online media channels. FNMG’s intended purposes are to deliver market updates and news alerts issued from private and publicly trading companies as well as providing coverage and increased awareness for companies that issue press to the public via online newswires. FNMG and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. The companies that are discussed in this release may or may not have approved the statements made in this release. Information in this release is derived from a variety of sources that may or may not include the referenced company’s publicly disseminated information. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. While this information is believed to be reliable, such reliability cannot be guaranteed. FNMG disclaims any and all liability as to the completeness or accuracy of the information contained and any omissions of material fact in this release. This release may contain technical inaccuracies or typographical errors. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. Investment in the securities of the companies discussed in this release is highly speculative and carries a high degree of risk. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. This release is not without bias, and is considered a conflict of interest if compensation has been received by FNMG for its dissemination. To comply with Section 17(b) of the Securities Act of 1933, FNMG shall always disclose any compensation it has received, or expects to receive in the future, for the dissemination of the information found herein on behalf of one or more of the companies mentioned in this release. For current services performed FNMG has been compensated forty six hundred dollars for Relevium Technologies Inc. current news coverage by a non-affiliated third party. FNMG HOLDS NO SHARES OF Relevium Technologies Inc.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.